Corbett TH - Search Results

1

Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.

Polin L, White K, Kushner J, Paluch J, Simpson C, Pugh S, Edelstein MK, Hazeldine S, Fontana J, LoRusso P, Horwitz JP, Corbett TH. Polin L, et al. Among authors: corbett th. Invest New Drugs. 2002 Feb;20(1):13-22. doi: 10.1023/a:1014469828729. Invest New Drugs. 2002. PMID: 12003190

2

Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30.

Poondru S, Parchment RE, Purohit V, LoRusso P, Horwitz JP, Hazeldine ST, Polin L, Corbett T, Jasti BR. Poondru S, et al. Invest New Drugs. 2002 Feb;20(1):23-33. doi: 10.1023/a:1014457510073. Invest New Drugs. 2002. PMID: 12003192

3

Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Corbett TH, White K, Polin L, Kushner J, Paluch J, Shih C, Grossman CS. Corbett TH, et al. Invest New Drugs. 2003 Feb;21(1):33-45. doi: 10.1023/a:1022912208877. Invest New Drugs. 2003. PMID: 12795528

4

5-Fluorouracil containing combinations in murine tumor systems.

Corbett TH, Bissery MC, Mucci-LoRusso P, Polin L. Corbett TH, et al. Invest New Drugs. 1989 Apr;7(1):37-49. doi: 10.1007/BF00178190. Invest New Drugs. 1989. PMID: 2661481 Review.

5

Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.

Tapazoglou E, Polin L, Corbett TH, al-Sarraf M. Tapazoglou E, et al. Among authors: corbett th. Invest New Drugs. 1988 Dec;6(4):259-64. doi: 10.1007/BF00173643. Invest New Drugs. 1988. PMID: 3068184

6

Comparative efficacy of DMP 840 against mouse and human solid tumor models.

LoRusso P, Demchik L, Dan M, Polin L, Gross JL, Corbett TH. LoRusso P, et al. Among authors: corbett th. Invest New Drugs. 1995;13(3):195-203. doi: 10.1007/BF00873800. Invest New Drugs. 1995. PMID: 8729946

7

Preclinical antitumor activity of CI-994.

LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR 3rd, Corbett TH. LoRusso PM, et al. Among authors: corbett th. Invest New Drugs. 1996;14(4):349-56. doi: 10.1007/BF00180810. Invest New Drugs. 1996. PMID: 9157069

8

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.

Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett TH. Polin L, et al. Among authors: corbett th. Invest New Drugs. 1997;15(2):99-108. doi: 10.1023/a:1005856605726. Invest New Drugs. 1997. PMID: 9220288

9

Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).

Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH. Foster BJ, et al. Among authors: corbett th. Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398. Invest New Drugs. 1997. PMID: 9387041

10

Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.

Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R. Corbett TH, et al. Invest New Drugs. 1997;15(3):207-18. doi: 10.1023/a:1005875015011. Invest New Drugs. 1997. PMID: 9387043 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters